Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $9.42B | $87.13 | $122.60 | 40.72% | Buy | 5 | 39.19% | 138.07% | 172.24% | 136.79% | |||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $4.00B | $31.81 | $42.50 | 33.61% | Strong Buy | 4 | 22.97% | 116.97% | 151.00% | 68.18% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.69B | $72.98 | $91.29 | 25.08% | Strong Buy | 7 | 19.64% | 34.17% | 38.00% | 27.74% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $30.46B | $227.66 | $354.06 | 55.52% | Strong Buy | 17 | 20.57% | 29.08% | 186.00% | 45.31% | |||
| HALO | HALOZYME THERAPEUTICS INC | $14.53B | $128.01 | $104.14 | -18.64% | Buy | 7 | 12.31% | 51.68% | 769.40% | 42.85% | |||
| KRYS | KRYSTAL BIOTECH INC | $9.28B | $313.66 | $384.43 | 22.56% | Strong Buy | 7 | 26.81% | 15.24% | 63.71% | 57.71% | |||
| VCEL | VERICEL CORP | $2.20B | $43.04 | $60.67 | 40.95% | Strong Buy | 3 | 14.74% | 40.78% | 22.72% | 16.72% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.79B | $55.75 | $91.18 | 63.54% | Strong Buy | 17 | 13.63% | 157.05% | 27.42% | 14.79% | |||
| RPRX | ROYALTY PHARMA PLC | $37.24B | $64.76 | $65.60 | 1.30% | Strong Buy | 5 | 16.16% | 49.99% | 42.19% | 20.83% | |||
| TGTX | TG THERAPEUTICS INC | $8.39B | $54.79 | $64.00 | 16.81% | Buy | 4 | 27.79% | 8.97% | 101.32% | 37.33% | |||
| ADMA | ADMA BIOLOGICS INC | $2.48B | $11.07 | $17.50 | 58.16% | Strong Buy | 2 | 13.23% | 17.15% | 83.21% | 49.64% | |||
| MDXG | MIMEDX GROUP INC | $561.18M | $3.85 | $7.33 | 90.47% | Strong Buy | 3 | 2.36% | 82.72% | 13.77% | 10.58% | |||
| EXEL | EXELIXIS INC | $16.13B | $65.11 | $53.55 | -17.76% | Hold | 11 | 11.31% | 15.64% | 66.89% | 49.45% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $6.15B | $308.30 | $352.63 | 14.38% | Strong Buy | 8 | 16.34% | 13.35% | 29.02% | 12.85% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $13.35B | $205.70 | $296.56 | 44.17% | Strong Buy | 18 | 6.29% | 26.42% | 43.06% | 18.66% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $565.93M | $9.53 | $26.88 | 182.00% | Strong Buy | 8 | 18.48% | 11.46% | 77.72% | 55.88% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $131.16B | $517.49 | $555.18 | 7.28% | Strong Buy | 11 | 9.91% | 13.29% | 37.13% | 27.41% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.14B | $36.83 | $47.67 | 29.42% | Buy | 6 | 10.97% | 17.79% | 23.24% | 16.92% | |||
| UTHR | UNITED THERAPEUTICS CORP | $25.43B | $592.84 | $634.38 | 7.01% | Buy | 8 | 9.68% | 7.52% | 30.47% | 27.01% | |||
| TECH | BIO-TECHNE CORP | $11.40B | $72.69 | $68.33 | -5.99% | Hold | 11 | 8.41% | 31.56% | 19.90% | 16.22% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $83.15B | $807.67 | $824.95 | 2.14% | Strong Buy | 21 | 9.53% | 18.92% | 24.05% | 18.28% | |||
| VCYT | VERACYTE INC | $3.87B | $48.20 | $57.78 | 19.87% | Strong Buy | 9 | 9.83% | 11.86% | 11.84% | 11.06% | |||
| SPRO | SPERO THERAPEUTICS INC | $62.31M | $1.07 | $6.00 | 460.75% | Buy | 1 | -14.69% | 17.91% | N/A | N/A | |||
| INCY | INCYTE CORP | $22.97B | $113.31 | $128.12 | 13.07% | Buy | 17 | 4.53% | 8.44% | 12.85% | 10.36% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.